Three physicians from the Cleveland Clinic discuss strategies for selecting the Impella® heart pump and/or ECMO as well as patient management and venting strategies.
Seth Bilazarian, MD, discusses the limitations of Schrage, Ibrahim, et al. published in Circulation comparing patients in cardiogenic shock treated with balloon pump and the Impella® heart pump.
The NCSI Study is based on adopting the best practices algorithm focused on identifying shock early and unloading using Impella devices before PCI, reducing use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.
The STEMI DTU pilot trial demonstrated for the first time that LV unloading using the Impella CP® heart pump with a 30-minute delay before reperfusion is safe and feasible
The clinical, preclinical, and basic research of A-CURE focuses primarily on the use of the Impella® heart pump, a transvalvular microaxial flow pump, as the means to unload the heart.
This study shows that presence of CTO in patients with coronary artery disease (CAD) with ischemic heart failure results in adverse long-term prognosis.
Watch how Impella 2.5® provides hemodynamic support during Protected PCI.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
